{"entity":{"id":"sara-lopez-tarruella","kind":"person","name":"Sara López-Tarruella","aka":[],"tldr":"Sara López-Tarruella is a breast oncologist leading GEICAM neoadjuvant studies in triple-negative disease.","summary":"Sara López-Tarruella is a medical oncologist at Hospital General Universitario Gregorio Marañón in Madrid. Her specialisms are breast cancer, triple-negative disease and neoadjuvant trials, and she leads GEICAM neoadjuvant studies of chemotherapy and immunotherapy in triple-negative and HER2-positive breast cancer. Her papers include a Future Oncology piece on how to treat HR-positive, HER2-negative early breast cancer, a study of docetaxel, carboplatin and doxorubicin activity in patient-derived triple-negative xenografts, and an Annals of Oncology report on the TNBC-DX genomic test in early triple-negative breast cancer treated with neoadjuvant taxane-based therapy. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lopez-Tarruella%20S%5BAuthor%5D%20breast%20neoadjuvant"}],"tags":[],"related":[],"cancers":["tnbc","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gregorio-maranon"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["future-oncology"],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Hospital General Universitario Gregorio Marañón","institutionId":"gregorio-maranon","specialisms":["Breast cancer","Triple-negative disease","Neoadjuvant trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lopez-Tarruella%20S%5BAuthor%5D%20breast%20neoadjuvant"}],"papers":[{"title":"How we Treat HR-Positive, HER2-Negative Early Breast Cancer","journal":"Future Oncology","year":2022,"doi":"10.2217/fon-2021-0668"},{"title":"Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts","journal":"Scientific Reports","year":2021,"doi":"10.1038/s41598-021-85962-4"},{"title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","journal":"Annals of Oncology","year":2025,"doi":"10.1016/j.annonc.2024.10.012"}],"orcid":"0000-0002-2606-9538"},"route":"/people/sara-lopez-tarruella/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"institution":[{"id":"gregorio-maranon","kind":"institution","name":"Hospital General Universitario Gregorio Marañón","route":"/institutions/gregorio-maranon/"}],"journal":[{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/"}],"company":[{"id":"geicam","kind":"company","name":"GEICAM Spanish Breast Cancer Group","route":"/companies/geicam/"}]}}